摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(4S,5S)-2,3-didehydro-cephalotaxan-8-one | 691891-08-4

中文名称
——
中文别名
——
英文名称
(4S,5S)-2,3-didehydro-cephalotaxan-8-one
英文别名
(2S,6S)-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),3,13,15(19)-tetraen-9-one
(4S,5S)-2,3-didehydro-cephalotaxan-8-one化学式
CAS
691891-08-4
化学式
C17H17NO3
mdl
——
分子量
283.327
InChiKey
DQGHRAZLHQDWIO-SUMWQHHRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    469.3±45.0 °C(Predicted)
  • 密度:
    1.38±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    21
  • 可旋转键数:
    0
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.47
  • 拓扑面积:
    38.8
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    (-)-头孢他辛和C-7烷基化类似物的立体选择性合成
    摘要:
    报道了(-)-头孢他辛的总不对称合成。使用α,β-不饱和γ-内酰胺的化学反应,通过对映体纯的α-羟基亚胺鎓离子的半pinacolic重排,以对映体纯净的形式进入1-azaspiro [4.4]壬烷骨架。通过遵循Kuehne报告的外消旋合成,可将该螺化合物无任何消旋化或差向异构化地转化为(-)-头孢他辛。因此,我们在16个步骤的序列中以98.7%ee的总合成了(-)-头孢他辛,总产率为9.8%。该合成方法适合于某些烷基化类似物的获得。
    DOI:
    10.1021/jo049884l
  • 作为产物:
    描述:
    (6R)-7-[2-(3,4-methylenedioxyphenyl)ethyl]-1,4-dioxa-7-azadispiro[4.0.4.3]tridecan-8-one 在 、 palladium diacetate 、 四氯化锡 、 aluminum isopropoxide 、 溶剂黄146六甲基二硅氮烷 作用下, 以 硝基甲烷二氯甲烷乙腈 为溶剂, 反应 53.75h, 生成 (4S,5S)-2,3-didehydro-cephalotaxan-8-one
    参考文献:
    名称:
    (-)-头孢他辛和C-7烷基化类似物的立体选择性合成
    摘要:
    报道了(-)-头孢他辛的总不对称合成。使用α,β-不饱和γ-内酰胺的化学反应,通过对映体纯的α-羟基亚胺鎓离子的半pinacolic重排,以对映体纯净的形式进入1-azaspiro [4.4]壬烷骨架。通过遵循Kuehne报告的外消旋合成,可将该螺化合物无任何消旋化或差向异构化地转化为(-)-头孢他辛。因此,我们在16个步骤的序列中以98.7%ee的总合成了(-)-头孢他辛,总产率为9.8%。该合成方法适合于某些烷基化类似物的获得。
    DOI:
    10.1021/jo049884l
点击查看最新优质反应信息

文献信息

  • Nitroso-ene cyclization enabled access to 1-azaspiro[4.4]nonane and its application in a modular synthesis toward (±)-cephalotaxine
    作者:Sha-Hua Huang、Xuechao Tian、Xianwei Mi、Yan Wang、Ran Hong
    DOI:10.1016/j.tetlet.2015.10.002
    日期:2015.12
    In this communication, a nitroso-ene cyclization was devised to rapidly construct 1-azaspiro[4.4]nonane, a key structural motif which was further implemented into the modular synthesis of (+/-)-cephalotaxine (6). The whole synthesis route to access the key intermediate 7 involves eight steps from a commercially available 1,2-epoxycyclopentane (12) and five purifications on silica gel column. The direct nitroso-ene reaction to 1-azabicyclo[4.4]non-2-one paves a way to a future development of the practical synthesis of cephalotaxus alkaloids. (C) 2015 Published by Elsevier Ltd.
  • KUEHNE, MARTIN E.;BORNMANN, WILLIAM G.;PARSONS, WILLIAM H.;SPITZER, TIMOT+, J. ORG. CHEM., 53,(1988) N 15, 3439-3450
    作者:KUEHNE, MARTIN E.、BORNMANN, WILLIAM G.、PARSONS, WILLIAM H.、SPITZER, TIMOT+
    DOI:——
    日期:——
  • Stereoselective Synthesis of (−)-Cephalotaxine and C-7 Alkylated Analogues
    作者:Loïc Planas、Joëlle Pérard-Viret、Jacques Royer
    DOI:10.1021/jo049884l
    日期:2004.4.1
    A total asymmetric synthesis of (−)-cephalotaxine is reported. The chemistry of α,β-unsaturated γ-lactams was used to access the 1-azaspiro[4.4]nonane skeleton in enantiomerically pure form via a stereocontrolled semipinacolic rearrangement of an α-hydroxyiminium ion. This spiro compound was transformed into (−)-cephalotaxine without any racemization or epimerization by following the racemic synthesis
    报道了(-)-头孢他辛的总不对称合成。使用α,β-不饱和γ-内酰胺的化学反应,通过对映体纯的α-羟基亚胺鎓离子的半pinacolic重排,以对映体纯净的形式进入1-azaspiro [4.4]壬烷骨架。通过遵循Kuehne报告的外消旋合成,可将该螺化合物无任何消旋化或差向异构化地转化为(-)-头孢他辛。因此,我们在16个步骤的序列中以98.7%ee的总合成了(-)-头孢他辛,总产率为9.8%。该合成方法适合于某些烷基化类似物的获得。
查看更多

同类化合物

高三尖杉酯碱酰胺 高三尖杉酯碱 氧桥三尖杉碱 异三尖杉酯碱 双(去甲基)-脱氧三尖杉酯碱 去甲基三尖杉酮碱 去氧哈林通碱 乙酰三尖杉碱 三尖杉酯碱 三尖杉碱 4-羟基三尖杉碱 4'-去甲基高三尖杉酯碱 (1S,3aR)-1,5,6,8,9,14bbeta-六氢-2-甲氧基-4H-环戊并[a][1,3]二氧杂环戊并[4,5-H]吡咯并[2,1-b][3]苯并氮杂卓-1alpha,9alpha-二醇 (-)-脱水三尖杉酯碱 nordeoxyharringtonine cephalotaxine 4′-demethylharringtonine homoharringtonine α-N-oxide cephalotaxine α-N-oxide cephalotaxine α-N-oxide cephalotaxine β-N-oxide (2R,3R,4S,5S)-2,3-bis(tert-butyldiphenylsilyloxy)-cephalotaxan-8-one (2S,3R,5S,7S)-3-methyl-4,17,19-trioxa-11-azahexacyclo[12.7.0.02,7.03,5.07,11.016,20]henicosa-1(21),14,16(20)-triene (2S,6S)-3-methyl-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),3,13,15(19)-tetraene (1S)-2-methoxy-(3atC4,14bt)-1,5,6,8,9,14b-hexahydro-4H-1r,9c-epioxido-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepine 1-O-[(2R,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-O-methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate 2,3,5,6,8,9-hexahydro-1-(pivaloyloxy)-4H-cyclopenta<1,3>dioxolo<4,5-h>pyrrolo<2,1-b><3>benzazepine Dimethyl 3-(trifluoromethylsulfonyloxy)-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),2,7,13,15(19)-pentaene-7,8-dicarboxylate Alkaloid D Epicephalotaxin Cephalotaxin a u. b (3aα,4aS*,15bβ,15cα)-(+/-)-3a,4,6,7,9,10,15b,15c-octahydro-2,2-dimethyl-5H-<1,3>dioxolo<4,5-h>-1,3-dioxolo<4,5>cyclopenta<1,2-a>pyrrolo<2,1-b><3>-benzazepine 4-Hydroxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),13,15(19)-trien-3-one (Ξ)-2-methyl-2-(2,2,2-trichloro-ethoxycarbonyloxy)-butyric acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester (3aR)-2-methoxy-1t-(2,2,2-trichloro-ethoxycarbonyloxy)-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepine (S)-phenyl-(2,2,2-trichloro-ethoxycarbonyloxy)-acetic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester oxalic acid ethyl ester (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester (3aR)-1t-benzyloxycarbonyloxy-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepine (S)-hydroxy-phenyl-acetic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester [(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] (2R)-2-[2-(furan-2-ylmethylamino)-2-oxoethyl]-2,6-dihydroxy-6-methylheptanoate (+/-)-3-dehydroxy-2-demethoxy-1,2-dihydro-2,8-dioxocephalotaxine epi-deoxyharringtonine hexa-2t,4t-dienoic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester Dehydrodeoxyhomoharringtonine [(2S,4S,6S)-12-methylsulfanyl-11-oxo-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),13,15(19)-trien-4-yl] acetate Omacetaxine mepesuccinate hydrochloride cephalotaxinamide (1R,2S,3aS,14bR)-1,2,3,5,6,8,9,14b-Octahydro-4H-cyclopenta<1,3>dioxolo<4,5-h>pyrrolo<2,1-b><3>benzazepine-1,2-diol methylfumaric acid 1-((3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl) ester 4-methyl ester 11alpha-Hydroxycephalotaxine